佰仁医疗：控股子公司胶原蛋白植入剂产品获批注册

Core Viewpoint - The announcement by Baijun Medical (688198) regarding the approval of its collagen implant product marks a significant milestone in the domestic market for aesthetic medical products, specifically for facial treatments [1] Company Summary - Baijun Medical's subsidiary, Beijing Aibairui Biotechnology Co., Ltd., has received approval from the National Medical Products Administration for its collagen fiber filler product, which is the first of its kind in China for injection into the dermal layer of the cheeks to improve smoothness [1]